2022
The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma
Sher L, Passalacqua G, Taillé C, Cohn L, Daizadeh N, Pandit-Abid N, Soler X, Khodzhayev A, Jacob-Nara J, Deniz Y, Rowe P, Nag A, Zhang Y. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma. Annals Of Allergy Asthma & Immunology 2022, 130: 298-304. PMID: 36509407, DOI: 10.1016/j.anai.2022.12.002.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsSevere asthmaActivity limitationsDose reductionAQLQ scoresDupilumab groupWeek 24Open-label extensionProportion of patientsType 2 inflammationHuman monoclonal antibodyQuality of lifeOral corticosteroidsOCS useInterleukin-4Long-term effectsAsthmaPatientsSymptomsMonoclonal antibodiesSleepReceptor componentsDupilumabDyspneaWeeks
2021
REAL-WORLD EFFECTIVENESS OF DUPILUMAB ON PATIENT-REPORTED OUTCOMES AND SYMPTOMS IN ASTHMA: 3-MONTH FOLLOW-UP DATA FROM RESPIRE, AN OBSERVATIONAL STUDY WITH PATIENTS RECRUITED FROM A US DUPILUMAB PATIENT SUPPORT PROGRAM
Cohn L, Zhang Y, Wang J, Chen C, Ortiz B, Djandji M, Zhang S, Yang M, Zeiger R. REAL-WORLD EFFECTIVENESS OF DUPILUMAB ON PATIENT-REPORTED OUTCOMES AND SYMPTOMS IN ASTHMA: 3-MONTH FOLLOW-UP DATA FROM RESPIRE, AN OBSERVATIONAL STUDY WITH PATIENTS RECRUITED FROM A US DUPILUMAB PATIENT SUPPORT PROGRAM. CHEST Journal 2021, 160: a29-a30. DOI: 10.1016/j.chest.2021.07.075.Peer-Reviewed Original Research